ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNG Synairgen Plc

4.675
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.675 4.35 5.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.52 9.41M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.68p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.41 million. Synairgen has a price to earnings ratio (PE ratio) of -0.52.

Synairgen Share Discussion Threads

Showing 26626 to 26650 of 99175 messages
Chat Pages: Latest  1075  1074  1073  1072  1071  1070  1069  1068  1067  1066  1065  1064  Older
DateSubjectAuthorDiscuss
08/9/2020
07:08
Synairgen plc Positive interim analysis of SNG001 in COPDSource: UK Regulatory (RNS & others)TIDMSNGRNS Number : 2832YSynairgen plc08 September 2020Press releaseSynairgen plc('Synairgen' or the 'Company')Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients - SNG001 well tolerated in this older population with a significant co-morbidity (COPD) - Strong interferon driven antiviral biomarker response - Data support future progression of SNG001 for exacerbating COPD patients - Positive data supportive of SNG001 COVID-19 programme Southampton, UK - 8 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection.Key findings -- Safety SNG001 was well tolerated during the treatment period in a study population that was elderly (mean age 66 years) and suffering from reduced respiratory function, as measured by forced expiratory volume in one second (FEV1) (59% of predicted value). The percentage of on-treatment adverse events was similar in the placebo and SNG001 treatment groups (48.1% versus 45.6%, respectively), with treatment-related adverse events being more frequent in the placebo group (25%) compared to the SNG001 group (15.8%). This safety data add to the safety database for SNG001, supporting Synairgen's interactions with regulatory agencies in respect of COVID-19, where older age and poor lung function are risk factors. -- Antiviral activity Over the treatment period, lung antiviral responses to viral infection were significantly enhanced in patients receiving SNG001 compared to those on placebo, as assessed by measuring increases in the gene expression of interferon beta-dependent antiviral biomarkers MX1 (p=
nortic 007
08/9/2020
07:06
Excellent news!
dave444
08/9/2020
07:06
Mmmm.... RNS ..... not what i was expecting !
amaretto1
08/9/2020
07:00
Posted by ‘dafad’ on LSE:



How plentiful interferon production may help bats withstand C-19.

wetdream
Chat Pages: Latest  1075  1074  1073  1072  1071  1070  1069  1068  1067  1066  1065  1064  Older